Treatment of genital herpes in males with imiquimod 1% cream

Clinical Drug Investigation

Volumn 16, Issue 3, 1998, Pages 187-191

  Syed, Tanweer A ^a   Ahmadpour, Oliver Abbas ^b   Ahmad, Seyed Ali ^c   Shamsi, Sadaf ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c UNIVERSITY OF THE PUNJAB   (Pakistan)

^d Municipal Dispensary   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMIQUIMOD;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEVER; GENITAL HERPES; HEADACHE; HEALING; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SELF MEDICATION; SKIN MANIFESTATION; TOPICAL DRUG ADMINISTRATION; VIRUS CULTURE;

EID: 0031671751     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816030-00002     Document Type: Article

References (16)

1. Corey L. The current trend in genital herpes. Progress in prevention. Sex Transm Dis 1994; 21 (2 Suppl.): 38-44
2. Ebel C. Managing herpes, how to live and love with a chronic STD. North Carolina 27709. American Social Health Association. RTP, 1994: 123-34
3. Mertz GF. Herpes simplex virus. In: Galasso GJ, Whitley RJ, Merigan TC, editors. Antiviral agents and viral diseases of man. 3rd ed. New York: Raven Press, 1990: 265
4. Syed TA, Cheema KM, Kahlon BMM, et al. Human leukocyte interferon-alpha in cream for the treatment of genital herpes in Asian males. Dermalology 1995; 191: 32-5
5. Syed TA, Afzaz M, Ahmad SA, et al. Management of genital herpes in men with 0.5% aloe vera extract in a hydrophilic cream. A placebo-controlled, double-blind study. J Dermatol Treat 1997; 8: 99-102
6. Mertz GJ. Management of genital herpes. Adv Exp Med Biol 1996; 394: 1-10
7. Memar OM, Tyring SK. Antiviral agents in dermatology [review]. Current status and future prospectus. Int J Dermatol 1995; 34: 597-606
8. Bernstein DI, Miller RL, Harrison CJ. Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in receiving guinea-pigs when begun after lesion development. Antiviral Res 1993; 20: 45-55
9. Bernstein DI, Harrison CJ, Tepe ER, et al. Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs. Vaccine 1995; 13: 72-6
10. Van Dyck E, Piot P, Meheus A. Bench-lezel laboratory manual for sexually transmitted diseases. WHO/VDT/89.443. Geneva: WHO, 1989: 43-4
11. Ashley RL, Militoni J, Lee F, et al. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex types 1 and 2 in human sera. J Clin Microbiol 1988; 26: 662-7
12. De Clercq E. Antivirals for the treatment of herpes virus infections. J Antimicrob Chemother 1993; 32 Suppl. A: 121-32
13. Cheong WK. Development in the antiviral treatment of genital herpes. Ann Acad Med Singapore 1995; 24: 593-7
14. Ziegenmeyer J. The influence of the vehicle on the absorption and permeation of drugs. In: Brandau R, Lippold BH, editors. Dermal and transdermal absorption. Munich: Wissenschaftliche Verlagsgesellschaft. 1981: 73-86
15. Savage P, Horron V, Moore J, et al. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer 1996; 74: 1482-6
16. Wit PL, Ritch PS, Reding D, et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 1993; 53: 5176-80